Enobia was a private biopharmaceutical company based in Montreal, Canada, and Cambridge, Massachusetts. The company was dedicated to developing therapies for ultra-rare and life-threatening genetic metabolic disorders. Its lead product candidate, asfotase alfa (Strensiq), was designed to treat hypophosphatasia, a severe metabolic bone disease. In 2012, Enobia was acquired by Alexion (AstraZeneca) for $1.1B USD.
Hypophosphatasia
CTI LSF I
Co-Lead
Director
August 30, 2007
Enobia acquired by Alexion for $1.1B USD
Series B
Enobia had a first-in-class disease modifying treatment for a rare and life-threatening pediatric disease called hypophosphatasia
February 10, 2012
December 28, 2011
November 9, 2015
